4/10/15 Disclosures Grant/Research Support from: – LEO Pharma – Bristol-Myers Squibb Symptomatic & Incidental Sub-Segmental PE Marc Carrier MD MSc FRCPC Objectives • Review the incidence of sub-segmental pulmonary embolism (SSPE) – Are we overdiagnosing PE? – Are SSPE clinical important? • Propose a management strategy for patients with SSPE • Describe the incidence and management of incidental SSPE in cancer patients Ms. MT • 55 yo woman on HRT, presents to ER with SOB and pleuritic CP. • Likely PTP on Wells model + positive D-dimer • CTPA: single subsegmental filling defect in left upper lobe • Management options: 1. 2. 3. 4. LMWH + warfarin/VKA DOAC No anticoagulation + no further investigations US of lower limbs – No DVT then No anticoagulation Background • Pulmonary embolism (PE) is a common disease and associated with significant morbidity and mortality. Statement of the clinical problem and incidence of SSPE • For decades, clinicians have been taught that untreated PE has a high mortality and high risk of recurrent venous thromboembolism (VTE). • CTPA >>> VQ for diagnosis for PE – More available – Alternative diagnosis – Higher sensitivity for smaller vessels • Subsegmental pulmonary embolism (SSPE) 1 4/10/15 Increasing use of CTPA leads to rising rates of SSPE CTPA for diagnosis of PE • ER physician survey 16 x 0.75 mm 10 sec – 71% CTPA vs. 20% VQ 2-slice CT • Increase use of CTPA led to increase rates of SSPE diagnosis 1992 64 x 0.625 mm 4 sec 2 x 2.7 mm 25 sec 4-slice CT – 5.4% (95%CI: 4.1 to 6.7) 1998 4 x 1 mm 25 sec Weiss CR et al. Acad Radiol. 2006 Apr;13:434-46. Auer RC, et al. J Am Coll Surg 2009;208(5):871-8. 16-slice CT 2002 64-slice 2004 8/31 Increase incidence of SSPE with multiple detector CT Is SSPE a problem? Carrier M et al, J Thromb Haemost. 2010;8:1716-22. US Nationwide Inpatient Sample and Multiple Cause –of Death databases Wiener RS et al. Arch Int Med 2011;171:831-837. Are we now over-diagnosing PE? (i.e. SSPE not clinically important) Clinical importance of SSPE is unclear • US Nationwide Inpatient Sample and Multiple Cause –of Death databases\ – PE unchanged before CTPA but increased substantially after CTPA • ↑81% - from 62.1 to 112.3 per 100,000 (P < .001) – PE mortality decreased • ↓3% - from 12.3 to 11.9 per 100,000 (P = .02) – Case fatality improved • ↓36% - from 12.1% to 7.8% (P < .001) – CTPA was associated with an increase in presumed complications of anticoagulation for PE • ↑ 71% - from 3.1 to 5.3 per 100,000 (P < .001). Wiener RS et al. Arch Int Med 2011;171:831-837. Wiener RS et al. Arch Int Med 2011;171:831-837. 2 4/10/15 Are we now over-diagnosing PE? (i.e. SSPE not clinically important) Wiener RS et al. Arch Int Med 2011;171:831-837. Any other clues from the literature suggesting overdiagnosis? Anderson DR. JAMA. 2007;298:2743-53. How reliable is the diagnosis of SSPE on CTPA • 11% of SSPE were deemed false positive when re-read by an experienced thoracic radiologist • Positive predictive value of only 25% What did we do to make a diagnosis of PE before CT? • Low inter-observer variability – K: 0.38; (95%CI: 0.0-0.89) • EXPERIENCED thoracic radiologist should review all SSPE diagnosis Perrier A et al. Lancet 1999.353;190-5. Ghanima W et al. Acta Radiol 2007;48:165-70. PIOPED Study We feel comfortable with int V/Q. Why not CTPA? 17 % of patients with a low probability V/Q scan in PIOPED had a isolated SSPE on pulmonary angiography PIOPED. JAMA. 1990;263:2753-59. 3-month risk 0.6% (0.2 to 1.4%) Kearon C. CMAJ. 2003;168:183-194. 3 4/10/15 Do we need to do treat SSPE? Do we need to treat SSPE? Carrier M et al, J Thromb Haemost. 2010;8:1716-22. Any other clues from the literature? Risk of recurrent VTE and bleeding • Cohort of 2213 patients who underwent CTPA – 550 patients had PE (24.8%) – 82 patients had SSPE • 3.9% of total scans and 15.0% of PEs. – 43 patients (52%) received anticoagulation for SSPE. • Major life-threatening bleeding complications occurred 2 patients receiving anticoagulation – No documented recurrent VTE in any patients with SSPE, with or without anticoagulation. Anderson DR. JAMA. 2007;298:2743-53. Risk of recurrent VTE and bleeding • • • • Post-hoc analysis from two cohort studies 3728 patients with suspected PE 116/748 (16%) SSPE Risk of recurrent VTE – SSPE = Proximal PE – 3.6% vs. 2.5% (p=0.42) • However: – Small number of recurrent event – No bil leg US – More patients with lower symptoms of DVT in baseline characteristics Goy J et al J Thromb Haemost. 2015Feb;13(2):214-8. . What are the guidelines recommending? • ACCP – No specific recommendations • European Society of Cardiology – Individualized decision about anticoagulant therapy in patients with isolated SSPE and negative leg ultrasonography. – Anticoagulation vs. serial ultrasonography Den Exter PL et al Blood. 2013;122(7):1144-9. . 4 4/10/15 Conclusion • SSPE are frequent and clinical relevant is unclear. • CTPA examinations with isolated SSPE diagnosis should be reviewed by an experienced thoracic radiologist. Incidental SSPE in cancer patients • Patients with confirmed isolated SSPE and negative leg CUS may not require anticoagulation. • Prospective cohort management studies are required before withholding anticoagulant therapy becomes common practice in patients with isolated SSPE. Mr. MC • 25yo male with HD. • Routine computed tomography (CT) of the chest for cancer staging. • Called by the radiologist because single SSPE incidentally found on CT. What will you do? 1. Observation only (+/- repeating imaging) 2. LMWH in combination with VKA for minimum of 6 months 3. LMWH only (+/- dose reduction) for minimum of 6 months • Patients denies chest pain, shortness of breath or hemoptysis. • How will you manage Mr. MC? Risk of incidental PE in cancer patients 4. Rivaroxaban 15 mg BID X 3 weeks then 20 mg daily for minimum of 6 months Cumulative risk of recurrent VTE Incidental Vs. Symptomatic PE (all receiving anticoagulation) • Approx 1 to 4% of routine CT Chest staging – In-patients > outpatients Incidental PE: n=51 Symptomatic PE: n=144 • Risk factors: – Metastatic disease – Recent chemotherapy – Types of cancer: • Pancreas • Melanoma/skin • Hepatobiliary • Kidney • etc Browne AM et al. J Thorac Oncol. 2010;5:798-803. Douma RA et al. Thromb Res 2010; 25:e306-e309. Shinagore AB et al. Cancer. 2011; 117:3860-6. Figure from: den Exter P L et al. JCO 2011;29:2405-2409 5 4/10/15 Does size matter? • 70 patients with incidental PE and 137 matched cancer patients without incidental PE Risk of recurrent VTE and bleeding • Patient-level meta-analysis of incidental PE In cancer patients. – Risk of recurrent VTE • Incidental SSPE = more proximal PE • Risk of recurrent VTE was 56% in patients left untreated • But: – No bilateral leg US – Other cohort studies showed no difference – ? Risk of bleeding on oral anticoagulants Model stratified for type and stage, age, gender and location of metastases. Figure from: O’Connell C. et al. J Thromb Heamost 2011;9:305-311. van der Hulle T et al. Blood. 2014; Abstract 590. ISTH Cancer & Thrombosis SCC recommendations • In patients with isolated SSPE, we recommend careful review of the images by radiologists and suggest performing compression ultrasonography of the lower limbs to detect concomitant incidental DVT. • In patients with multiple SSPE, we recommend LMWH for at least 6 months. Di Nisio M et al. J Thromb Haemost. 2015 Feb 25. doi: 10.1111/jth.12883. [Epub ahead of print] ISTH Cancer & Thrombosis SCC recommendations • In patients with isolated SSPE with DVT, we recommend LMWH for at least 6 months. • In patients with isolated with distal DVT or without DVT, we suggest that the decision to provide anticoagulation is made on a case-by-case basis, considering the risk of bleeding, the presence of risk factors for recurrent thrombosis, performance status of the patient, and patient preference. If the decision is not to anticoagulate, we suggest performing serial bilateral compression ultrasonography after one week and clinical monitoring. Di Nisio M et al. J Thromb Haemost. 2015 Feb 25. doi: 10.1111/jth.12883. [Epub ahead of print] Thank You 6
© Copyright 2024